Pharma and Healthcare Market Analysis 2026

The commercial release of Voranigo (vorasidenib) by Servier Pharmaceuticals for the post-surgical treatment of adult and pediatric patients with grade 2 astrocytoma or oligodendroglioma bearing susceptible IDH1 or IDH2 mutations was approved by the US FDA. The patients must be 12 years of age or older. The "first-in-class" IDH1 and IDH2 inhibitor is voranigo. According to the press release, this is the first systemic medication that the FDA has authorized for the individuals listed above. A total of 331 patients participated in the double-blind, placebo-controlled, pivotal phase 3 clinical study named INDIGO, which assessed the effectiveness of Voranigo. 
Patients received 40 mg of Voranigo or placebo orally once a day until the illness progressed or the toxicity became intolerable in a 1:1 randomization. Patients who were randomly assigned to receive a placebo might switch to Voranigo if their condition progresses as shown by radiography. Time to next intervention (TTNI) and progression-free survival (PFS), as determined by an independent review committee that was blinded, were the main efficacy outcomes. According to trial data, PFS was 11.1 months for the placebo group and 27.7 months for the Voranigo group. 

Source Link: https://www.pharmexec.com/view/fda-approves-servier-voranigo-grade-2-idh-mutant-glioma

According to a report by The Economic Times, Mankind Pharma is competing with a consortium led by the Abu Dhabi Investment Authority (ADIA) and Europe's largest buyout company EQT to acquire BSV company (previously Bharat Serums and Vaccines) from Advent International. The estimated value of the deal is Rs 14,000 crore, or $1.67 billion
Mankind Pharma and EQT made proposals earlier this week, and despite being shortlisted at first, a group including Warburg Pincus, ChrysCapital, and Mubadala did not make a legally binding offer. A wide range of goods are offered by BSV, such as anesthetics, antitoxins, antifungals, monoclonal antibodies, fertility hormones, plasma derivatives, and diagnostic items. Due to the company's significant R&D emphasis, about 15 patents have been awarded in the US, Europe, Australia, and Japan, among other nations. Through the acquisition of Firstline Pharmaceuticals and Genomics in Malaysia as well as the human pharma sector of TTK Healthcare in India, BSV has recently increased its global footprint.

Source Link: https://www.business-standard.com/companies/news/mankind-pharma-and-eqt-compete-to-acquire-bsv-group-for-rs-14-000-crore-124071800409_1.html

Sun Pharmaceutical Industries Limited, along with its subsidiaries and affiliates, has entered into an agreement with HaystackAnalytics Private Limited "Haystack". Under this agreement, Sun Pharma will acquire a 9.6% stake in Haystack’s total outstanding securities. Haystack, registered under the Companies Act 2013 and based in Mumbai, develops genomic analysis software that aids clinical decision-making by providing comprehensive, rapid, and culture-free clinical genomics. Their technology automates bioinformatic analysis to produce clear, clinically relevant reports and leverages genomic data to create new healthcare products. Operating in the healthcare industry, Haystack's acquisition represents a non-material investment for Sun Pharma, aimed at expanding into related areas. This acquisition is not considered a related party transaction, and neither the promoter nor the promoter group has any interest in the entity whose securities are being acquired.

Source Link: https://www.angelone.in/blog/sun-pharma-expands-portfolio-acquisition-haystackanalytics

Discover how AI adoption and automation are revolutionizing the pharma and healthcare sectors. Read the comprehensive expert perspective from Cognitive Market Research & Consulting on predictive drug discovery, automated manufacturing, and end-to-end clinical solutions. Contact our leading consultants today to optimize your enterprise workflow.